ABSTRACT
O carcinoma espinocelular (CEC) apresenta a segunda maior taxa de incidência entre os cânceres de pele não melanoma. Cerca de 5% desses casos evoluem para lesões localmente avançadas e/ou metastáticas, tornando a abordagem cirúrgica muitas vezes inviável. Com base nisso, foi realizada uma revisão na literatura sobre o uso de imunoterápicos no tratamento do CEC avançado. Observou-se, então, que a imunoterapia é uma potencial estratégia terapêutica devido à promoção da atividade antitumoral por meio da própria resposta imunológica individual, o que contribui para a redução dos efeitos colaterais de cirurgias, quimioterapias e radioterapias.
Squamous cell carcinoma (SCC) has the second highest incidence rate among non-melanoma skin cancers. About 5% of cases progress to locally advanced and/or metastatic lesions, making the surgical approach often unfeasible. Based on this, we performed a literature review on the use of immunotherapy drugs to treat advanced SCC. The results showed that immunotherapy is a potential therapeutic strategy due to the antitumor activity promotion through the individual immune response, reducing the adverse events of surgeries, chemotherapy, and radiotherapy
ABSTRACT
For over twenty years, the Insitute of Immunopathology of Xi'an Medical University, the antecedent Institute of Cancer Research, has long been engaged in the study on tumor immunity. Beginning with the exploration of the mechanisims for the activation of tumor-infiltrating lymphocytes(TIL) and tumor evasion till translating the relevant achievements into tumor immunotherapy and immunoprevention. From one facet, all the facts reflect the arduous course of the struggle of human beings for conquering cancer.